You may think that with a price-to-sales (or “P/S”) ratio of 13.3x ProQR Therapeutics N.V. (NASDAQ:PRQR) is a stock to potentially avoid, seeing as almost half of all the Biotechs companies in the United States have P/S ratios under 10.4x and even P/S lower than 4x aren’t out of the ordinary. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s as high as it is.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Check out our latest analysis for ProQR Therapeutics

What Does ProQR Therapeutics’ Recent Performance Look Like?

ProQR Therapeutics could be doing…